Science - Allinky Biopharma

Scientific and clinical research have shown that sustained oxidative stress, chronic inflammatory condition and missignalling on cell progression are key factors in diseases such as Alzheimer's, ictus, rheumatoid arthritis, osteoarthritis, diabetes type II, atherosclerosis and certain types of cancer. Allinky is discovering novel therapeutics capable of modulating abnormal cell-molecular signals behind these diseases and thus contributing to restore normal cell-gene expression. These novel therapeutics are allosteric modulators that follow biological mechanisms to regulate undesired protein activation.

Allosteric modulation is the regulation of enzyme activity by binding an effector molecule at a site other than the protein's active site. This regulation may be more selective and more potent than the active site inhibition. In addition, allosteric modulators may target ubiquitous enzymes to down regulate their activation status rather than to inhibit their activity with side-effects. Recent scientific literature on allosteric modulation include the following:

• Goodey NM, Benkovic SJ. Allosteric regulation and catalysis emerge via a common route. Nat Chem Biol. 2008 Aug;4(8):474-82.
  

• Kamata K, Mitsuya M, Nishimura T, Eiki J, Nagata Y. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. Structure. 2004 Mar;12(3):429-38.
• Burgin AB. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol. 2010 Jan;28(1):63-70. Epub 2009 Dec 27.
• Chan WW et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011 Apr 12;19(4):556-68.
• Zhizhou Fang, Christian Grütter, and Daniel Rauh. Strategies for the selective regulation of kinases with allosteric regulators: exploiting exclusive structural features. ACS Chem. Biol. 2012 Dic 31.